Peptide half-life chart
Reference elimination half-lives for 82 peptides, from GLP-1 agonists like semaglutide and tirzepatide to research peptides like BPC-157 and TB-500. Each entry is labelled by evidence level so you can tell label data from community estimates.
Open the free half-life calculator
GLP-1 & incretins
| Peptide | Half-life | Route | Evidence |
|---|---|---|---|
| SemaglutideOzempic, Wegovy, Rybelsus | 6.9 days (range 6–7 days) | SC weekly / oral daily | Clinical |
| TirzepatideMounjaro, Zepbound | 5 days | SC weekly | Clinical |
| RetatrutideLY3437943 | 6 days (range 5.6–6.9 days) | SC weekly | Limited |
| LiraglutideVictoza, Saxenda | 13 h | SC daily | Clinical |
| DulaglutideTrulicity | 4.7 days | SC weekly | Clinical |
| ExenatideByetta | 2.4 h | SC twice daily | Clinical |
| LixisenatideAdlyxin, Lyxumia | 3 h | SC daily | Clinical |
| CagrilintideNN9838 | 7.3 days (range 6.6–8.1 days) | SC weekly | Limited |
| PramlintideSymlin | 48 min | SC with meals | Clinical |
| SurvodutideBI 456906 | 5 days (range 4.5–5.4 days) | SC weekly | Limited |
| MazdutideIBI362, LY3305677 | 8 days (range 7.3–10.8 days) | SC weekly | Limited |
GH secretagogues
| Peptide | Half-life | Route | Evidence |
|---|---|---|---|
| IpamorelinNNC 26-0161 | 2 h | SC / IV | Limited |
| CJC-1295 (no DAC)Mod GRF 1-29, Modified GRF (1-29), CJC-1295 without DAC | 30 min | SC | Anecdotal |
| CJC-1295 with DACDAC:GRF, CJC-1295 DAC | 7 days (range 5.8–8.1 days) | SC weekly | Limited |
| SermorelinGRF 1-29, Geref | 12 min (range 10–20 min) | SC | Clinical |
| TesamorelinEgrifta | 30 min (range 26–38 min) | SC daily | Clinical |
| GHRP-2Pralmorelin | 30 min (range 15 min–1 h) | SC | Limited |
| GHRP-6Growth hormone releasing peptide-6 | 30 min (range 15 min–1 h) | SC | Limited |
| HexarelinExamorelin | 1.2 h | SC / IV | Limited |
| IbutamorenMK-677, MK-0677 | 5 h (range 4–6 h) | Oral daily | Limited |
| AnamorelinAdlumiz, ONO-7643 | 7 h | Oral daily | Clinical |
| MacimorelinMacrilen | 4.1 h | Oral (diagnostic) | Clinical |
GH & IGF-1
| Peptide | Half-life | Route | Evidence |
|---|---|---|---|
| SomatropinHGH, Human growth hormone, Genotropin, Norditropin, Humatrope, Omnitrope | 3.5 h (range 2–5 h) | SC daily | Clinical |
| SomapacitanSogroya | 2.5 days (range 2–3 days) | SC weekly | Clinical |
| PegvisomantSomavert | 6 days (range 3.1–7.2 days) | SC daily | Clinical |
| MecaserminIncrelex, rhIGF-1, IGF-1 | 5.8 h | SC twice daily | Clinical |
| IGF-1 LR3Long R3 IGF-1, LR3 | 25 h (range 20–30 h) | SC | Anecdotal |
| IGF-1 DESDES(1-3) IGF-1 | 30 min | SC / IM | Anecdotal |
| PEG-MGFPegylated mechano growth factor | 2 days | SC / IM | Anecdotal |
| MGFMechano growth factor, IGF-1Ec | 6 min | IM | Anecdotal |
Healing & repair
| Peptide | Half-life | Route | Evidence |
|---|---|---|---|
| BPC-157Body Protection Compound 157, PL 14736, Bepecin | 30 min (range 8–30 min) | SC / oral | Limited |
| Thymosin beta-4Tβ4, TB4, Timbetasin | 1.5 h (range 30 min–2.1 h) | IV / SC | Limited |
| TB-500Ac-LKKTETQ, Thymosin beta-4 fragment | 1.5 h | SC | Anecdotal |
| GHK-CuCopper peptide, Copper tripeptide-1 | 1 h | SC / topical | Anecdotal |
| KPVLys-Pro-Val, α-MSH (11-13) | 1 h | SC / oral | Anecdotal |
| LL-37Cathelicidin | 1 h | SC | Anecdotal |
| ARA-290Cibinetide | 2 min | SC / IV | Limited |
Melanocortins
| Peptide | Half-life | Route | Evidence |
|---|---|---|---|
| Melanotan IIMT-II, MT2, Melanotan 2 | 1 h | SC | Limited |
| Melanotan IAfamelanotide, MT-I, Scenesse | 1.2 h (range 48 min–1.7 h) | SC / implant | Limited |
| BremelanotidePT-141, Vyleesi | 2.7 h | SC as needed | Clinical |
| SetmelanotideImcivree | 11 h | SC daily | Clinical |
Reproductive & hormonal
| Peptide | Half-life | Route | Evidence |
|---|---|---|---|
| Kisspeptin-10KP-10 | 4 min | IV / SC | Limited |
| Kisspeptin-54KP-54, Metastin | 28 min | IV / SC | Limited |
| GonadorelinGnRH, Factrel, LHRH | 18 min (range 10–40 min) | SC / IV | Clinical |
| hCGHuman chorionic gonadotropin, Pregnyl, Novarel, Ovidrel | 30 h (range 23–36 h) | SC / IM | Clinical |
| GanirelixFyremadel, Orgalutran | 16 h (range 13–16 h) | SC daily | Clinical |
| TriptorelinTrelstar, Triptodur, Decapeptyl | 2.8 h | IM / SC | Clinical |
| LeuprolideLeuprorelin, Lupron | 3 h | SC / IM | Clinical |
| OxytocinPitocin, Syntocinon | 3 min (range 1–6 min) | IV / IM / intranasal | Clinical |
| CarbetocinDuratocin, Pabal | 40 min | IV / IM | Clinical |
| DesmopressinDDAVP, Noctiva | 2.8 h (range 1.5–3.5 h) | SC / IV / intranasal / oral | Clinical |
| VasopressinVasostrict, ADH, Arginine vasopressin | 10 min | IV | Clinical |
Nootropic & neuro
Longevity & mitochondrial
| Peptide | Half-life | Route | Evidence |
|---|---|---|---|
| EpitalonEpithalon, AEDG, Epitalone | 30 min | SC | Anecdotal |
| MOTS-cMitochondrial ORF of the 12S rRNA type-c | 30 min | SC | Anecdotal |
| ElamipretideSS-31, Forzinity, Bendavia, MTP-131 | 1.5 h (range 1–2 h) | SC daily | Limited |
| HumaninHN, HNG | 30 min | SC | Anecdotal |
| Thymosin alpha-1Thymalfasin, Zadaxin, Tα1 | 2 h (range 1.6–2 h) | SC | Clinical |
| GlutathioneGSH, L-glutathione | 10 min | IV / IM | Limited |
Metabolic & endocrine
| Peptide | Half-life | Route | Evidence |
|---|---|---|---|
| AOD-9604hGH fragment 177-191 (Tyr), Advanced Obesity Drug | 30 min | SC | Anecdotal |
| TesofensineNS2330 | 9.2 days | Oral daily | Limited |
| MetreleptinMyalept, Leptin | 4.3 h (range 3.8–4.7 h) | SC daily | Clinical |
| TeduglutideGattex, Revestive, GLP-2 analog | 2 h | SC daily | Clinical |
| OctreotideSandostatin | 1.7 h | SC | Clinical |
| LanreotideSomatuline Depot | 23 days (range 23–30 days) | Deep SC monthly depot | Clinical |
| PasireotideSignifor | 12 h | SC twice daily | Clinical |
| SomatostatinSST-14, GHIH | 2 min | IV | Clinical |
| TeriparatideForteo, PTH (1-34) | 1 h | SC daily | Clinical |
| AbaloparatideTymlos | 1.7 h | SC daily | Clinical |
| Calcitonin (salmon)Miacalcin, Calcitonin | 1 h | SC / IM / intranasal | Clinical |
| GlucagonGlucaGen, Gvoke, Baqsimi | 30 min | SC / IM / intranasal | Clinical |
| DasiglucagonZegalogue | 30 min | SC | Clinical |
Insulins
| Peptide | Half-life | Route | Evidence |
|---|---|---|---|
| Insulin lisproHumalog, Admelog, Lyumjev | 1 h | SC | Clinical |
| Insulin aspartNovoLog, Fiasp, NovoRapid | 1.4 h | SC | Clinical |
| Insulin glulisineApidra | 42 min | SC | Clinical |
| Regular human insulinHumulin R, Novolin R, Insulin regular | 1.5 h | SC | Clinical |
| Insulin detemirLevemir | 7 h (range 5–7 h) | SC | Clinical |
| Insulin glargineLantus, Toujeo, Basaglar, Semglee | 12 h (range 12–19 h) | SC daily | Clinical |
| Insulin degludecTresiba | 25 h | SC daily | Clinical |